Search results for "Antimalarial"

showing 8 items of 58 documents

Naphthalene Derivatives from the Roots of Pentas parvifolia and Pentas bussei

2016

The phytochemical investigation of the CH2Cl2/MeOH (1:1) extract of the roots of Pentas parvifolia led to the isolation of three new naphthalenes, parvinaphthols A (1), B (2), and C (3), two known anthraquinones, and five known naphthalene derivatives. Similar investigation of the roots of Pentas bussei afforded a new polycyclic naphthalene, busseihydroquinone E (4), a new 2,2'-binaphthralenyl-1,1'-dione, busseihydroquinone F (5), and five known naphthalenes. All purified metabolites were characterized by NMR and MS data analyses, whereas the absolute configurations of 3 and 4 were determined by single-crystal X-ray diffraction studies. The E-geometry of compound 5 was supported by DFT-base…

StereochemistryPlasmodium falciparumPharmaceutical SciencePentasAnthraquinonesRubiaceaeCrystallography X-Ray010402 general chemistryPlant Roots01 natural sciencesAnalytical ChemistryAntimalarialsInhibitory Concentration 50chemistry.chemical_compoundBreast cancer cell lineDrug DiscoveryAnthraquinonesIc50 valuesHumansNuclear Magnetic Resonance Biomolecularta116naphthalene derivativesNaphthalenenaphthalenesPharmacologyPentasMolecular Structurebiology010405 organic chemistryOrganic Chemistryta1182Pentas parvifoliabiology.organism_classificationphytochemicals0104 chemical sciencesComplementary and alternative medicinechemistryPhytochemicalMolecular MedicineJournal of Natural Products
researchProduct

Mbandakamine-Type Naphthylisoquinoline Dimers and Related Alkaloids from the Central African Liana Ancistrocladus ealaensis with Antiparasitic and An…

2018

Four new dimeric naphthylisoquinoline alkaloids, michellamine A5 (2) and mbandakamines C–E (4–6), were isolated from the Congolese plant Ancistrocladus ealaensis, along with the known dimer mbandakamine A (3). They represent constitutionally unsymmetric dimers, each consisting of two 5,8′-coupled naphthylisoquinoline monomers. While the molecular halves of michellamine A5 (2) are linked via C-6′ of both of the naphthalene moieties, i.e., via the least-hindered positions, so that the central biaryl axis is configurationally unstable and not an additional element of chirality, the mbandakamines 3–6 possess three consecutive stereogenic axes. Their monomeric units are linked through an unprece…

Steric effectsAntiparasiticmedicine.drug_classStereochemistryDimerPlasmodium falciparumPharmaceutical ScienceNaphthalenes010402 general chemistry01 natural sciencesAnalytical ChemistryStereocenterchemistry.chemical_compoundAntimalarialsAlkaloidsCell Line TumorDrug DiscoverymedicineHumansAfrica CentralAncistrocladus ealaensisPharmacologyMichellamineAntiparasitic Agents010405 organic chemistryOrganic ChemistryIsoquinolinesAntineoplastic Agents PhytogenicCaryophyllales0104 chemical sciencesMonomerComplementary and alternative medicinechemistryQuinolinesMolecular MedicineChirality (chemistry)Journal of natural products
researchProduct

S2k guideline for treatment of cutaneous lupus erythematosus - guided by the European Dermatology Forum (EDF) in cooperation with the European Academ…

2016

Cutaneous lupus erythematosus (CLE) is a rare inflammatory autoimmune disease with heterogeneous clinical manifestations. To date, no therapeutic agents have been licensed specifically for patients with this disease entity, and topical and systemic drugs are mostly used 'off-label'. The aim of the present guideline was to achieve a broad consensus on treatment strategies for patients with CLE by a European subcommittee, guided by the European Dermatology Forum (EDF) and supported by the European Academy of Dermatology and Venereology (EADV). In total, 16 European participants were included in this project and agreed on all recommendations. Topical corticosteroids remain the mainstay of trea…

Systemic diseasemedicine.medical_specialtyVenereologyConsensusCalcineurin InhibitorsDermatologyDapsone030207 dermatology & venereal diseases03 medical and health sciencesAntimalarialsRetinoids0302 clinical medicineAdrenal Cortex HormonesmedicineLupus Erythematosus CutaneousHumans610 Medicine & healthlupus erythematous cuteneous guidelines treatmentLenalidomideLenalidomide030203 arthritis & rheumatologyBiological ProductsLupus erythematosusbusiness.industryfungiGuidelineMycophenolic Acidmedicine.diseaseDermatologyThalidomideClinical trialThalidomideInfectious DiseasesMethotrexatePractice Guidelines as TopicbusinessDapsoneImmunosuppressive Agentsmedicine.drug
researchProduct

Antileukemic ancistrobenomine B and related 5,1′-coupled naphthylisoquinoline alkaloids from the Chinese liana Ancistrocladus tectorius

2017

A striking feature of the metabolite pattern of the Southeast Asian liana Ancistrocladus tectorius (Ancistrocladaceae) is the predominance of 5,1′-coupled naphthylisoquinoline alkaloids. About 20 alkaloids of this coupling type have so far been discovered in this plant species. Here, we report on the isolation of four new 5,1′-linked naphthylisoquinolines from the twigs and stems of A. tectorius. Two of them, the ancistrobenomines B (5) and C (6), belong to the very rare group of alkaloids with a fully dehydrogenated isoquinoline portion. Likewise unusual for naphthylisoquinoline alkaloids is the presence of a hydroxymethylene group at C-3. Within the large class of meanwhile ca. 180 such n…

Trypanosoma brucei rhodesienseCircular dichroismStereochemistryMetabolitePlasmodium falciparumNaphthalenesSoutheast asian01 natural sciencesAntimalarialsMagnoliopsidachemistry.chemical_compoundAlkaloidsCell Line TumorDrug DiscoveryHumansIsoquinolinePharmacologyMolecular StructurePlant Stemsbiology010405 organic chemistryTrypanosoma brucei rhodesiensePlasmodium falciparumGeneral MedicineIsoquinolinesbiology.organism_classificationAntineoplastic Agents Phytogenic0104 chemical sciences010404 medicinal & biomolecular chemistrychemistryAncistrocladaceaeTwo-dimensional nuclear magnetic resonance spectroscopyFitoterapia
researchProduct

A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19

2020

Purpose COVID-19 (coronavirus disease 2019) is a public health emergency of international concern. As of this time, there is no known effective pharmaceutical treatment, although it is much needed for patient contracting the severe form of the disease. The aim of this systematic review was to summarize the evidence regarding chloroquine for the treatment of COVID-19. Methods PubMed, EMBASE, and three trial Registries were searched for studies on the use of chloroquine in patients with COVID-19. Results We included six articles (one narrative letter, one in-vitro study, one editorial, expert consensus paper, two national guideline documents) and 23 ongoing clinical trials in China. Chloroqui…

medicine.medical_specialtyChinaCoronaviruPneumonia ViralPsychological interventionMEDLINEDiseaseCritical Care and Intensive Care MedicineWorld Health OrganizationArticle03 medical and health sciencesAntimalarialsBetacoronavirus0302 clinical medicineChloroquinePandemicmedicineHumansIntensive care medicinePandemicsClinical Trials as Topicbusiness.industrySARS-CoV-2Public healthCOVID-19030208 emergency & critical care medicineChloroquinePneumoniaCOVID-19 Drug TreatmentClinical trialCoronavirusClinical researchTreatment Outcome030228 respiratory systembusinessCoronavirus Infectionsmedicine.drugJournal of Critical Care
researchProduct

Hyperpigmentation of hard palate induced by chloroquine therapy

2017

The antimalarials are one of the most commonly prescribed drugs for conditions such as lupus erythematosus and rheumatoid arthritis, and the side effects, though infrequent, are well known. The antimalarial agent chloroquine diphosphate usually causes pigmentary changes in the oral mucosa characterized by a bluish-grey to black discolorations mainly in the hard palate. Considering only the hard palate hyperpigmentation caused by chloroquine, to the best of our knowledge, only 13 cases have been reported in the English language literature. We described an additional case of palate hyperpigmentation related to the chronic use of chloroquine diphosphate in a 60-year-old Mexican woman. Although…

medicine.medical_specialtyMedication historyCase Report03 medical and health sciences0302 clinical medicineChloroquinemedicineAntimalarial AgentOral mucosaAdverse effectGeneral DentistryOral Medicine and Pathologybusiness.industry030206 dentistrymedicine.disease:CIENCIAS MÉDICAS [UNESCO]HyperpigmentationDermatologymedicine.anatomical_structure030220 oncology & carcinogenesisRheumatoid arthritisUNESCO::CIENCIAS MÉDICASHard palatemedicine.symptombusinessmedicine.drug
researchProduct

Synthesis and Molecular Modeling Studies of Derivatives of a Highly Potent Peptidomimetic Vinyl Ester as Falcipain-2 Inhibitors

2012

Herein we report the synthesis of a set of constrained peptidomimetics endowed with an electrophilic vinyl ester warhead and structurally related to a previously identified lead compound, a potent and irreversible inhibitor of falcipain-2 (FP-2). FP-2 is the main hemoglobinase of the malaria parasite P. falciparum. The new compounds were evaluated for their inhibition against FP-2, and the results were rationalized on the basis of docking experiments. These studies underscore the pivotal role of both the ester function at the P1' site and the trifluoromethyl group of the P3 side chain in determining the correct orientation of the Michael acceptor warhead in the catalytic site, and as a cons…

peptidomimeticdMolecular modelPeptidomimeticStereochemistryPlasmodium falciparumVinyl esterBiochemistrycysteine proteasesfalcipain-2 inhibitorsAntimalarialschemistry.chemical_compoundCatalytic DomainDrug DiscoverySide chainHumansEnzyme InhibitorsMalaria FalciparumGeneral Pharmacology Toxicology and PharmaceuticsPharmacologyTrifluoromethylOrganic Chemistrydocking studiescysteine proteases; peptidomimeticd; docking studies; falcipain-2 inhibitorsMolecular Docking SimulationCysteine EndopeptidaseschemistryDocking (molecular)Michael reactionMolecular MedicinePeptidomimeticsLead compoundChemMedChem
researchProduct

Amphoteric polyamidoamines in the treatment of malaria

2012

The present invention relates to the use of amphoteric polyamidoamines with MW of 10-100 kDa as antimalarial agents or carriers of antimalarial drugs and to formulations thereof.

polyamidoamines malaria antimalarial chloroquine primaquine
researchProduct